Avelumab Related Merkel Cell Carcinoma: Biological Plausibility Explained
Legacy of General Health Information and the Shift to Occupational Exposure
The legacy of general health and science information dissemination has long served as a foundation for public understanding of medical risks and therapeutic interventions. Within this broad context, the transition from population-level health guidance to specific occupational exposure considerations requires careful framing. Historically, health communications have addressed environmental and lifestyle factors, yet the shift toward evaluating pharmaceutical agents in workplace settings demands a more targeted analytical lens. This is particularly relevant when considering the biological plausibility of adverse outcomes following exposure to immunomodulatory therapies. The bridge concept here moves from general health literacy toward a focused examination of how therapeutic compounds may interact with occupational environments. Specifically, the discussion now pivots to consider the potential for avelumab exposure—whether through manufacturing, administration, or accidental contact—to influence cellular pathways relevant to Merkel cell carcinoma risk. This transition acknowledges that while general health information provides a necessary backdrop, the occupational context introduces distinct variables such as dose frequency, duration of exposure, and co-occurring workplace hazards. The following analysis will therefore explore the mechanistic rationale underlying such concerns without venturing into disease-specific claims, maintaining a neutral academic tone throughout.
Mechanism of Action and Therapeutic Use of Avelumab
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294;https://pubmed.ncbi.nlm.nih.gov/29799096). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). While avelumab is a therapeutic agent for MCC, the question of whether it can cause or contribute to the development of MCC requires examination of biological plausibility, mechanistic pathways, and risk considerations.
Etiology of Merkel Cell Carcinoma and Role of Immune Checkpoint Inhibitors
Merkel cell carcinoma has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by UV light, leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer durations of response compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). However, about 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab is known to cause overactivation of the immune system, leading to irAEs, including cases of hypercalcemia secondary to reactivation of sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781). These irAEs are a recognized consequence of checkpoint inhibitor therapy, but they do not directly implicate avelumab in causing de novo MCC.
Evidence Against Causal Link Between Avelumab and MCC Development
The biological plausibility of avelumab causing MCC is not supported by the available evidence. Avelumab is used to treat existing MCC, and its mechanism of action—blocking PD-L1 to enhance T-cell responses—is intended to combat tumors, not induce them. In fact, immune checkpoint inhibitors are associated with improved outcomes in MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). For patients who become refractory to avelumab, subsequent treatment with ipilimumab plus nivolumab has shown efficacy, with three out of five patients in one study responding to combined therapy (https://pubmed.ncbi.nlm.nih.gov/33439294). This suggests that avelumab does not cause MCC but rather is a standard therapy for it. No evidence in the provided snippets indicates that avelumab triggers the development of MCC through any mechanistic pathway, such as oncogenesis or viral reactivation. The known irAEs from avelumab, such as sarcoidosis reactivation, are inflammatory in nature and not linked to MCC causation (https://pubmed.ncbi.nlm.nih.gov/31543781).
Risk Considerations and Clinical Implications
Regarding risk anchors, the adequacy of warnings about avelumab and MCC must be considered. Avelumab is specifically approved for metastatic MCC, and its prescribing information likely includes warnings about irAEs, but the provided evidence does not include specific warning language. For affected patients, causation-related considerations are critical: if a patient develops MCC after avelumab exposure, the timeline must be evaluated. MCC is a rare cancer with a known viral and UV-related etiology, and avelumab is used as a treatment, not a cause. The timeline between exposure and documented harm would need to show that MCC developed after avelumab initiation, but given that avelumab is given to patients with existing MCC, any new MCC diagnosis would likely be progression of the original disease or a new primary tumor unrelated to the drug. The evidence does not support a causal link; rather, avelumab is associated with improved outcomes in MCC patients. In summary, the evidence does not establish biological plausibility for avelumab causing Merkel cell carcinoma. Avelumab is a therapeutic agent for MCC, and its use is associated with immune-related adverse events, but not with the induction of MCC. Patients and clinicians should be aware that avelumab is a treatment for MCC, and any new or worsening MCC during therapy is more likely due to disease progression or other factors than to the drug itself. Further research may clarify long-term risks, but current data do not support a causal relationship.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, the available evidence does not support a causal link. Avelumab is a treatment for Merkel cell carcinoma, and its mechanism of action is to enhance the immune response against tumors, not to induce them. Studies show improved outcomes in patients treated with avelumab for MCC.
What is the biological plausibility of avelumab causing MCC?
Biological plausibility is low because avelumab targets PD-L1 to activate T-cells against cancer cells. It is not known to cause oncogenesis or viral reactivation that could lead to MCC. The known side effects are immune-related adverse events, which are inflammatory and not linked to MCC development.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.